Physician profile
Samuel C Woolbert
NPI 1154318681
$6,017.21
in general payments reported to CMS, 2019-2025
34 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $367 · 2021: $1,352 · 2022: $1,037 · 2023: $838 · 2024: $647 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,621.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $551.85 | 2019-2022 | |
| Novo Nordisk INC | $516.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $389.68 | 2021-2025 | Verquvo, Capvaxive |
| Astellas Pharma US INC | $357.15 | 2019-2023 | Lexiscan |
| Esperion Therapeutics, INC. | $317.71 | 2020-2024 | Nexletol, Nexlizet |
| Amgen INC. | $236.71 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $235.84 | 2021-2023 | |
| Heartflow, INC. | $218.91 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $209.27 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.12 | 2019-2025 | Lifevest |
| Philips North America LLC | $157.14 | 2023-2025 | Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.62 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $108.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $92.21 | 2023-2025 | Onpattro, Amvuttra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $85.40 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.94 | 2021-2022 | |
| Bridgebio Pharma, INC. | $67.81 | 2025 | Attruby |
| Boston Scientific Corporation | $64.91 | 2019-2021 | |
| Althera Pharmaceuticals LLC | $43.19 | 2022 | |
| Arbor Pharmaceuticals, INC. | $42.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $36.37 | 2020-2022 | |
| Abiomed | $35.74 | 2021 | |
| Medtronic Vascular, INC. | $32.80 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $31.12 | 2019-2025 | Evkeeza |
| Edwards Lifesciences Corporation | $31.05 | 2020 | |
| Itamar Medical INC | $31.00 | 2022-2023 | Watchpatone |
| Vifor Pharma, INC. | $24.90 | 2019 | |
| Abbott Laboratories | $24.29 | 2021 | |
| Cook Medical LLC | $19.38 | 2023 | Zilver Ptx |
| Kiniksa Pharmaceuticals International, Plc | $17.87 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $13.99 | 2024 | Edarbyclor |
| Kowa Pharmaceuticals America, INC. | $12.65 | 2021 | |
| Lundbeck LLC | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Woolbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.